{'fraction_non_alphanumeric': 0.030120481927710843, 'fraction_numerical': 0.016566265060240965, 'mean_word_length': 5.157407407407407, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Phase I, II studies of recombinant granulocyte colony stimulating factor (gamma hG-CSF)].

Results obtained in phase I-II studies of gamma hG-CSF were reviewed. An optimal dose of Japanese patients with malignant diseases was judged to be 100-200 micrograms/m2 by 30 minutes infusion and 75 micrograms per body by subcutaneous injection. Neutrophils were increased dose-related while other blood components did not increase. When gamma hG-CSF was used following chemotherapy, it enhanced the nadirs of leukopenia and reduced significantly durations of neutropenic periods. Bone pain was characteristic side effect and occurred dose-dependently but generally mild.